newsfilter
← Latest News
Business Wire·

Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics

Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc.